Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and real-time intelligence to enhance their market performance.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights from Benzinga reporters.
IONS
$78.37+Infinity%1D
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 84.33 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 84.33 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 79.760
Low
65.00
Averages
84.33
High
110.00
Current: 79.760
Low
65.00
Averages
84.33
High
110.00
BofA
Jason Gerberry
Buy
maintain
$86 -> $97
2025-12-09
Reason
BofA
Jason Gerberry
Price Target
$86 -> $97
2025-12-09
maintain
Buy
Reason
BofA analyst Jason Gerberry raised the firm's price target on Ionis Pharmaceuticals to $97 from $86 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.
H.C. Wainwright
Buy
maintain
$100 -> $110
2025-11-10
Reason
H.C. Wainwright
Price Target
$100 -> $110
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ionis Pharmaceuticals to $110 from $100 and keeps a Buy rating on the shares. The firm believes Olezarsen is positioned to become the new standard for severe hypertriglyceridemia.
Piper Sandler
Overweight
maintain
$70 -> $77
2025-11-04
Reason
Piper Sandler
Price Target
$70 -> $77
2025-11-04
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Ionis Pharmaceuticals to $77 from $70 and keeps an Overweight rating on the shares. The firm notes the company reported a solid Q3 print with total revenue of $157M, including $32M from Tryngolza sales. Piper commend this name's recent commercial execution and continue to like the set-up on shares given near- and intermediate-term portfolio expansion opportunities across wholly owned and partnered assets.
TD Cowen
Buy
upgrade
$59 -> $99
2025-10-30
Reason
TD Cowen
Price Target
$59 -> $99
2025-10-30
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Ionis Pharmaceuticals to $99 from $59 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results driven by Tryngolza beat/raise. Cowen is adding $1.5B in peak global sales to theirmodel at $25k/yr.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
